Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Executive Summary
Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.
You may also be interested in...
US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.
OTC Switch For Naloxone Finding Interest Among Sponsors
Now that US FDA is about to complete label comprehension study, sponsors seem more positive about OTC versions of naloxone products.
OTC Switch For Naloxone Finding Interest Among Sponsors
With FDA 'si label comprehension study near completion, sponsors seem more positive about OTC versions of naloxone products. FDA has made clear it is interested in switching the product from Rx-only but had trouble generating sponsor desire to develop it.